Chao Lv, Haoan He, Mi Lin, Wei Li, Wenxin Mu, Bin Cheng, Xiaoan Tao
{"title":"Adaptively increased intake of arginine sustains oral keratinocyte survival through alleviating oxidative stress during targeting glutamine metabolism.","authors":"Chao Lv, Haoan He, Mi Lin, Wei Li, Wenxin Mu, Bin Cheng, Xiaoan Tao","doi":"10.1016/j.bcp.2025.117165","DOIUrl":null,"url":null,"abstract":"<p><p>Glutamine is a crucial amino acid with a variety of important roles in both health and disease, with ASCT2 (alanine-serine-cysteine transporter 2)-mediated uptake being critical for cellular homeostasis. While ASCT2 inhibition has been proposed as a therapeutic strategy for oral malignancies, our prior work revealed its paradoxical pro-tumorigenic effects in oral squamous cell carcinoma (OSCC), underscoring the complexity of glutamine metabolism targeting. Here, we identify a compensatory arginine-dependent survival mechanism in oral epithelial cells under glutamine restriction. ASCT2-knockout mice exhibit homeostasis in proliferation and apoptosis through SLC7A2 (solute carrier family 7 member 2) upregulation, a process driven by ROS/NF-κB signaling. Increased intracellular arginine serves as an effector for mTOR/S6 activation to promote cell growth in response to glutamine restriction. Additionally, arginine uptake could effectively alleviate oxidative stress and reduce cell apoptosis via the synthesis of glutathione (GSH) and the activation of NRF2/HO-1 signaling upon ASCT2 knockdown. These results not only delineate the metabolic reprogramming cascade mediated through ASCT2 suppression, but more importantly, reveal a clinically actionable strategy of dual glutamine-arginine metabolic intervention with translational promise for overcoming therapy resistance across multiple pathological states, particularly in malignancies exhibiting metabolic plasticity.</p>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":" ","pages":"117165"},"PeriodicalIF":5.3000,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.bcp.2025.117165","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Glutamine is a crucial amino acid with a variety of important roles in both health and disease, with ASCT2 (alanine-serine-cysteine transporter 2)-mediated uptake being critical for cellular homeostasis. While ASCT2 inhibition has been proposed as a therapeutic strategy for oral malignancies, our prior work revealed its paradoxical pro-tumorigenic effects in oral squamous cell carcinoma (OSCC), underscoring the complexity of glutamine metabolism targeting. Here, we identify a compensatory arginine-dependent survival mechanism in oral epithelial cells under glutamine restriction. ASCT2-knockout mice exhibit homeostasis in proliferation and apoptosis through SLC7A2 (solute carrier family 7 member 2) upregulation, a process driven by ROS/NF-κB signaling. Increased intracellular arginine serves as an effector for mTOR/S6 activation to promote cell growth in response to glutamine restriction. Additionally, arginine uptake could effectively alleviate oxidative stress and reduce cell apoptosis via the synthesis of glutathione (GSH) and the activation of NRF2/HO-1 signaling upon ASCT2 knockdown. These results not only delineate the metabolic reprogramming cascade mediated through ASCT2 suppression, but more importantly, reveal a clinically actionable strategy of dual glutamine-arginine metabolic intervention with translational promise for overcoming therapy resistance across multiple pathological states, particularly in malignancies exhibiting metabolic plasticity.
期刊介绍:
Biochemical Pharmacology publishes original research findings, Commentaries and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.
The journal''s target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.
All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complimentary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.
While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.